350 related articles for article (PubMed ID: 21317532)
1. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells.
Lukasova M; Malaval C; Gille A; Kero J; Offermanns S
J Clin Invest; 2011 Mar; 121(3):1163-73. PubMed ID: 21317532
[TBL] [Abstract][Full Text] [Related]
2. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
3. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
4. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
Li X; Millar JS; Brownell N; Briand F; Rader DJ
Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic acid receptor GPR109A is down-regulated in human macrophage-derived foam cells.
Chai JT; Digby JE; Ruparelia N; Jefferson A; Handa A; Choudhury RP
PLoS One; 2013; 8(5):e62934. PubMed ID: 23658787
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in niacin and lipid metabolism.
Kamanna VS; Ganji SH; Kashyap ML
Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
[TBL] [Abstract][Full Text] [Related]
7. Overexpressing human GPR109A leads to pronounced reduction in plasma triglyceride levels in BAC transgenic rats.
Masuda Y; Kurikawa N; Nishizawa T
Atherosclerosis; 2018 May; 272():182-192. PubMed ID: 29625294
[TBL] [Abstract][Full Text] [Related]
8. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
9. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
Pike NB
J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206
[TBL] [Abstract][Full Text] [Related]
11. Inflammation stimulates niacin receptor (GPR109A/HCA2) expression in adipose tissue and macrophages.
Feingold KR; Moser A; Shigenaga JK; Grunfeld C
J Lipid Res; 2014 Dec; 55(12):2501-8. PubMed ID: 25320346
[TBL] [Abstract][Full Text] [Related]
12. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
13. Enhanced ABCG1 expression increases atherosclerosis in LDLr-KO mice on a western diet.
Basso F; Amar MJ; Wagner EM; Vaisman B; Paigen B; Santamarina-Fojo S; Remaley AT
Biochem Biophys Res Commun; 2006 Dec; 351(2):398-404. PubMed ID: 17070501
[TBL] [Abstract][Full Text] [Related]
14. SR-BI inhibits ABCG1-stimulated net cholesterol efflux from cells to plasma HDL.
Yvan-Charvet L; Pagler TA; Wang N; Senokuchi T; Brundert M; Li H; Rinninger F; Tall AR
J Lipid Res; 2008 Jan; 49(1):107-14. PubMed ID: 17960026
[TBL] [Abstract][Full Text] [Related]
15. EP 80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions.
Marleau S; Harb D; Bujold K; Avallone R; Iken K; Wang Y; Demers A; Sirois MG; Febbraio M; Silverstein RL; Tremblay A; Ong H
FASEB J; 2005 Nov; 19(13):1869-71. PubMed ID: 16123174
[TBL] [Abstract][Full Text] [Related]
16. Niacin inhibits skin dendritic cell mobilization in a GPR109A independent manner but has no impact on monocyte trafficking in atherosclerosis.
Ingersoll MA; Potteaux S; Alvarez D; Hutchison SB; van Rooijen N; Randolph GJ
Immunobiology; 2012 May; 217(5):548-57. PubMed ID: 21798616
[TBL] [Abstract][Full Text] [Related]
17. Distinct kinetic and spatial patterns of protein kinase C (PKC)- and epidermal growth factor receptor (EGFR)-dependent activation of extracellular signal-regulated kinases 1 and 2 by human nicotinic acid receptor GPR109A.
Li G; Deng X; Wu C; Zhou Q; Chen L; Shi Y; Huang H; Zhou N
J Biol Chem; 2011 Sep; 286(36):31199-212. PubMed ID: 21768093
[TBL] [Abstract][Full Text] [Related]
18. Independent protective roles for macrophage Abcg1 and Apoe in the atherosclerotic lesion development.
Lammers B; Out R; Hildebrand RB; Quinn CM; Williamson D; Hoekstra M; Meurs I; Van Berkel TJ; Jessup W; Van Eck M
Atherosclerosis; 2009 Aug; 205(2):420-6. PubMed ID: 19217108
[TBL] [Abstract][Full Text] [Related]
19. Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling.
Pagler TA; Wang M; Mondal M; Murphy AJ; Westerterp M; Moore KJ; Maxfield FR; Tall AR
Circ Res; 2011 Jan; 108(2):194-200. PubMed ID: 21148432
[TBL] [Abstract][Full Text] [Related]
20. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins.
Wang N; Lan D; Chen W; Matsuura F; Tall AR
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9774-9. PubMed ID: 15210959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
